NASDAQ · Biotechnology

Cellectis S.A. (CLLS) Stock

$2.81 -2.26% NASDAQ: CLLS Healthcare

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies.

Valuation

MetricValue
Price$2.81
Market Cap$282.17M
P/E Ratio-4.14
P/B Ratio4.69
P/S Ratio2.97
EPS (TTM)$-0.68
52-Week High$5.48
52-Week Low$1.77
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-80.61%
ROA-23.26%
ROCE-30.50%
Gross Margin78.86%
Operating Margin-69.23%
Net Margin-98.69%
Debt/Equity1.38
Current Ratio1.52

Annual Financials (USD)

Metric20212022202320242025
Revenue$30.0M$19.0M$1.0M$42.0M$73.0M
Operating Profit$-103.0M$-90.0M$-97.0M$-60.0M$-33.0M
Net Profit$-114.0M$-106.0M$-101.0M$-37.0M$-68.0M
EPS$-1.93$-2.33$-1.77$-0.41$-0.68
Op Margin-341.0%-467.7%-12887.7%-143.5%-45.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$382.0M$261.0M$334.0M$384.0M$325.0M
Total Liabilities$146.0M$135.0M$250.0M$253.0M$249.0M
Cash$186.0M$90.0M$137.0M$143.0M$64.0M
Borrowings$101.0M$76.0M$85.0M$91.0M$120.0M

Latest News

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio GlobeNewswire · Jul 15, 2026 European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading MT Newswires · Jul 8, 2026 Monthly information on share capital and company voting rights GlobeNewswire · Jul 2, 2026 European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading MT Newswires · Jul 2, 2026 European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading MT Newswires · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-105.0M$-87.0M$-25.0M$22.0M$-40.0M
Investing Cash Flow$-11.0M$-5.0M$-17.0M$-105.0M$-32.0M
Financing Cash Flow$14.0M$8.0M$-10.0M$-11.0M$-11.0M
Net Cash Flow$-56.0M$-92.0M$43.0M$7.0M$-80.0M
Free Cash Flow$-123.0M$-90.0M$-26.0M$20.0M$-43.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA-5.55
FCF Yield-19.79%
Quick Ratio1.52
Interest Coverage-5.58
Return 1Y18.88%
Return 3Y15.42%
Return 5Y-80.14%

Ownership

Insiders Held0.00%
Institutions Held16.54%
Institutions Float Held16.54%
Institutional HolderSharesReport Date
B Group, Inc. 3,281,5012026-03-31
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3,178,6202026-03-31
Long Focus Capital Management, LLC2,744,0982026-03-31
Blackrock Inc.341,5232026-03-31
Nomura Asset Management International Inc226,8752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
ALDX $1.60 +3.23% -2.77 $96.51M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%
DBVTDBV Technologies S.A. $15.84 +0.83% -3.27 $378.92M 0.00%

About Cellectis S.A.

Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.

Cellectis S.A. is headquartered in FR.

Cellectis S.A. (CLLS) stock trades at $2.81 with a market capitalization of $282.17M. The stock is valued at a price-to-earnings (P/E) ratio of -4.14, price-to-book of 4.69, price-to-sales of 2.97. Over the past 52 weeks the stock has ranged between $1.77 and $5.48, and currently trades 48.7% below its 52-week high.

On profitability, Cellectis S.A. generates a return on equity (ROE) of -80.61%, return on capital employed of -30.50%, an operating margin of -69.23%, a net profit margin of -98.69%.

Official website: www.cellectis.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides